News | February 18, 2008

Triple Drug Therapy Reduces MACE in AFib Treated with PCI

February 19, 2008 - A regimen of aspirin, clopidogrel and coumadin started at discharge decreased mortality and major adverse cardiac events (MACE) while keeping bleeding to acceptable levels in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) with stent placement, reports a study in the February 26, 2008 issue of the Journal of the American College of Cardiology.

The researchers in the study, led by Gregory Y.H. Lip, MD, of City Hospital (Birmingham, UK), advise not to use drug-eluting stents (DES) in patients with AF requiring anticoagulation because of the increased bleeding risk that would accompany the addition of prolonged dual antiplatelet therapy.

The study included 426 elderly patients (mean age 71.5 years) with AF undergoing PCI with stenting at 2 hospitals in Spain between 2001 and 2006. Half of the patients were discharged with triple therapy (coumadin, aspirin, and clopidogrel). After 2 years of follow-up, patients who were not on coumadin at discharge had significantly higher rates of mortality, MACE, and other adverse events as compared with patients who were on a regimen including coumadin when they left the hospital.

In the study, patients given DES (n=174, 40.1% of cohort) had a higher rate of stent thrombosis (2.8% vs. 0%, P=0.034). This fact, combined with the necessity for prolonged dual antiplatelet therapy compared with bare-metal stents (BMS), convinced the study authors to recommend against the use of DES in anti-coagulated AF patients.

The study authors noted that deciding on the proper anticoagulant/antiplatelet regimen in AF patients undergoing PCI amounts to a balancing act in each individual, in which the risk of bleeding (increased in triple therapy) must be weighed against the risk of stroke, stent thrombosis, and other ischemic events (increased with AF and stent implantation).

The study concluded: “in those patients with AF treated with PCI/stents who have a low risk of bleeding complications, a triple-therapy regimen should be the elective antithrombotic drug treatment approach.”

In an editorial accompanying the study, Steven Francescone, M.D., and Jonathan L. Halperin, M.D., both of the Mount Sinai Medical Center (New York, NY), agreed that “for those at low risk of serious bleeding, treatment with triple therapy may be the best option.”

In addition, they wrote that, “BMS may be preferable to DES in patients with AF who have risk factors for thromboembolism requiring chronic anticoagulation to reduce the need for prolonged combination therapy.”

For more information:

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
New Study Focuses on Protein Responsible For Increased Heart Disease Risk
News | Cardiac Diagnostics| August 03, 2017
August 3, 2017 — A study to reduce the strongest inherited...
Overlay Init